{'fraction_non_alphanumeric': 0.012254901960784314, 'fraction_numerical': 0.0, 'mean_word_length': 5.923728813559322, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Renal transplantation in a patient with alport syndrome and cardiac dysfunction: Role of levosimendan

Anesthetic management in patients with end-stage renal disease and cardiac dysfunction coming for renal transplant is very challenging since the maintenance of adequate cardiac output is essential for good graft function. Levosimendan is an inodilator that increases cardiac output without increasing cardiac workload. Hence, it is the drug of choice in patients with ischemic heart disease and congestive cardiac failure. We present successful perioperative management of a renal transplant recipient with left ventricular dysfunction using levosimendan for maintenance of stable hemodynamics. Levosimendan, an inodilator, can be safely used in patients with cardiac dysfunction coming for renal transplantation.